Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Carrato, A; Garcia, P; Lopez, R; Macarulla, T; Rivera, F; Sastre, J; Gostkorzewicz, J; Benedit, P; Perez-Alcantara, F.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

Expert Review of Pharmacoeconomics & Outcomes Research. 2015; 15(4): 579-589 Nº de citas: 12 [doi:10.1586/14737167.2015.1047349]

Cajal, TRY; Chirivella, I; Miranda, J; Teule, A; Izquierdo, A; Balmana, J; Sanchez-Heras, AB; Llort, G; Fisas, D; Lope, V; Hernandez-Agudo, E; Juan-Fita, MJ; Tena, I; Robles, L; Guillen-Ponce, C; Perez-Segura, P; Luque-Molina, MS; Hernando-Polo, S; Salinas, M; Brunet, J; Salas-Trejo, MD; Barnadas, A; Pollan, M.

Mammographic density and breast cancer in women from high risk families

BREAST CANCER RESEARCH. 2015; 17: Nº de citas: 21 [doi:10.1186/s13058-015-0604-1]

Capdevila, J; Sevilla, I; Alonso, V; Aparicio, LA; Fonseca, PJ; Grande, E; Reina, JJ; Manzano, JL; Lajara, JDA; Barriuso, J; Castellano, D; Medina, J; Lopez, C; Segura, A; Carrera, S; Crespo, G; Fuster, J; Munarriz, J; Alfonso, PG.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

BMC CANCER. 2015; 15: Nº de citas: 25 [doi:10.1186/s12885-015-1512-6]

Larkin, J; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Cowey, CL; Lao, CD; Schadendorf, D; Dummer, R; Smylie, M; Rutkowski, P; Ferrucci, PF; Hill, A; Wagstaff, J; Carlino, MS; Haanen, JB; Maio, M; Marquez-Rodas, I; McArthur, GA; Ascierto, PA; Long, GV; Callahan, MK; Postow, MA; Grossmann, K; Sznol, M; Dreno, B; Bastholt, L; Yang, A; Rollin, LM; Horak, C; Hodi, FS; Wolchok, JD.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2015; 373(1): 23-34 Nº de citas: 7145 [doi:10.1056/NEJMoa1504030]

Martin, M.

nab-Paclitaxel dose and schedule in breast cancer

BREAST CANCER RESEARCH. 2015; 17: Nº de citas: 27 [doi:10.1186/s13058-015-0587-y]

Tejera-Alhambra, M; Casrouge, A; de Andres, C; Seyfferth, A; Ramos-Medina, R; Alonso, B; Vega, J; Fernandez-Paredes, L; Albert, ML; Sanchez-Ramon, S.

Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis

PLoS One. 2015; 10(6): Nº de citas: 47 [doi:10.1371/journal.pone.0128952]

Martin, M; Gonzalez-Rivera, M; Morales, S; de la Haba-Rodriguez, J; Gonzalez-Cortijo, L; Manso, L; Albanell, J; Gonzalez-Martin, A; Gonzalez, S; Arcusa, A; de la Cruz-Merino, L; Rojo, F; Vidal, M; Galvan, P; Aguirre, E; Morales, C; Ferree, S; Pompilio, K; Casas, M; Caballero, R; Goicoechea, U; Carrasco, E; Michalopoulos, S; Hornberger, J; Prat, A.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

CURRENT MEDICAL RESEARCH AND OPINION. 2015; 31(6): 1129-1137 Nº de citas: 34 [doi:10.1185/03007995.2015.1037730]

Castello, A; Martin, M; Ruiz, A; Casas, AM; Baena-Canada, JM; Lope, V; Antolin, S; Sanchez, P; Ramos, M; Anton, A; Munoz, M; Bermejo, B; De Juan-Ferre, A; Jara, C; Chacon, JI; Jimeno, MA; Rosado, P; Diaz, E; Guillem, V; Lluch, A; Carrasco, E; Perez-Gomez, B; Vioque, J; Pollan, M.

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

PLoS One. 2015; 10(5): Nº de citas: 65 [doi:10.1371/journal.pone.0126096]

Gelmon, KA; Boyle, FM; Kaufman, B; Huntsman, DG; Manikhas, A; Di Leo, A; Martin, M; Schwartzberg, LS; Lemieux, J; Aparicio, S; Shepherd, LE; Dent, S; Ellard, SL; Tonkin, K; Pritchard, KI; Whelan, TJ; Nomikos, D; Nusch, A; Coleman, RE; Mukai, H; Tjulandin, S; Khasanov, R; Rizel, S; Connor, AP; Santillana, SL; Chapman, JAW; Parulekar, WR.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(14): 1574 Nº de citas: 149 [doi:10.1200/JCO.2014.56.9590]

Cheang, MCU; Martin, M; Nielsen, TO; Prat, A; Voduc, D; Rodriguez-Lescure, A; Ruiz, A; Chia, S; Shepherd, L; Ruiz-Borrego, M; Calvo, L; Alba, E; Carrasco, E; Caballero, R; Tu, DS; Pritchard, KI; Levine, MN; Bramwell, VH; Parker, J; Bernard, PS; Ellis, MJ; Perou, CM; Di Leo, A; Carey, LA.

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

ONCOLOGIST. 2015; 20(5): 474-482 Nº de citas: 172 [doi:10.1634/theoncologist.2014-0372]

Tabernero, J; Yoshino, T; Cohn, AL; Obermannova, R; Bodoky, G; Garcia-Carbonero, R; Ciuleanu, TE; Portnoy, DC; Van Cutsem, E; Grothey, A; Prausova, J; Garcia-Alfonso, P; Yamazaki, K; Clingan, PR; Lonardi, S; Kim, TW; Simms, L; Chang, SC; Nasroulah, F.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

LANCET ONCOLOGY. 2015; 16(5): 499-508 Nº de citas: 793 [doi:10.1016/S1470-2045(15)70127-0]

Garcia-Alfonso, P; Chaves, M; Munoz, A; Salud, A; Garcia-Gonzalez, M; Gravalos, C; Massuti, B; Gonzalez-Flores, E; Queralt, B; Lopez-Ladron, A; Losa, F; Gomez, MJ; Oltra, A; Aranda, E.

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

BMC CANCER. 2015; 15: Nº de citas: 8 [doi:10.1186/s12885-015-1293-y]

Strasser-Weippl, K; Horick, N; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Boyle, F; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Rappold, E; Finkelstein, DM; Goss, PE.

Long-term hazard of recurrence in HER2+breast cancer patients untreated with anti-HER2 therapy

BREAST CANCER RESEARCH. 2015; 17: Nº de citas: 28 [doi:10.1186/s13058-015-0568-1]

Marquez-Rodas, I; Gonzalez, MM; Nagore, E; Gomez-Fernandez, C; Aviles-Izquierdo, JA; Maldonado-Seral, C; Soriano, V; Majem-Tarruella, M; Palomar, V; Maseda, R; Martin-Carnicero, A; Puertolas, T; Godoy, E; Cerezuela, P; de Olza, MO; Campos, B; Perez-Ruiz, E; Soria, A; Gil-Arnaiz, I; Gonzalez-Cao, M; Galvez, E; Arance, A; Belon, J; de la Cruz-Merino, L; Martin-Algarra, S.

Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study

PLoS One. 2015; 10(4): Nº de citas: 7 [doi:10.1371/journal.pone.0124239]

Gruenberger, T; Bridgewater, J; Chau, I; Alfonso, PG; Rivoire, M; Mudan, S; Lasserre, S; Hermann, F; Waterkamp, D; Adam, R.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

ANNALS OF ONCOLOGY. 2015; 26(4): 702-708 Nº de citas: 293 [doi:10.1093/annonc/mdu580]

Manso, L; Moreno, F; Marquez, R; Castelo, B; Arcediano, A; Arroyo, M; Ballesteros, AI; Calvo, I; Echarri, MJ; Enrech, S; Gomez, A; del Val, RG; Lopez-Miranda, E; Martin-Angulo, M; Martinez-Janez, N; Olier, C; Zamora, P.

Use of bevacizumab as a first-line treatment for metastatic breast cancer

Current Oncology. 2015; 22(2): 51-60 Nº de citas: 18 [doi:10.3747/co.22.2210]

Boyle, FM; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Amonkar, M; Huang, YJ; Rappold, E; Williams, LS; Wang-Silvanto, J; Kaneko, T; Finkelstein, DM; Goss, PE.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

EUROPEAN JOURNAL OF CANCER. 2015; 51(6): 685-696 Nº de citas: 12 [doi:10.1016/j.ejca.2015.02.005]

Garcia-Alfonso, P; Garcia-Foncillas, J; Salazar, R; Perez-Segura, P; Garcia-Carbonero, R; Musulen-Palet, E; Cuatrecasas, M; Landolfi, S; Cajal, SRY; Navarro, S.

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical & Translational Oncology. 2015; 17(4): 264-273 Nº de citas: 10 [doi:10.1007/s12094-014-1252-0]